Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€5.44
25.03.24
€10.00
25.03.25
-29.87%
28.04.24

WatchMen 
25.03.24 50%
buy
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.91
28.06.23
€7.00
31.01.26
-26.34%
28.04.24

Could be very worthwhile Investment >20% year
BiotechBee 
28.06.23 70%
buy
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€1.47
19.04.24
-
19.04.25
-2.04%
28.04.24

michaelkr 
19.04.24 50%
buy
Fibrogen Inc.

Start price
Target price
Perf. (%)
€1.07
19.04.24
-
19.04.25
-11.96%
28.04.24

Could be very worthwhile Investment >20% year
michaelkr 
19.04.24 50%
buy
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.52
23.04.24
-
23.04.25
-13.07%
28.04.24

michaelkr 
23.04.24 50%
buy
Enlivex Therapeutics Ltd.

Start price
Target price
Perf. (%)
€1.51
14.04.24
-
14.04.25
-9.27%
28.04.24

thomasw 
14.04.24 50%
buy
aTyr Pharma Inc

Start price
Target price
Perf. (%)
€1.66
14.04.24
-
14.04.25
-10.24%
28.04.24

Could be worthwhile Investment >10% per year
thomasw 
14.04.24 50%
buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€1.63
16.04.24
-
16.04.25
-15.41%
28.04.24

thomasw 
16.04.24 50%
buy
Thermo Fisher Scientific Inc.

Start price
Target price
Perf. (%)
€531.40
27.03.24
-
27.04.24
0.87%
28.04.24

MBU 
27.03.24 50%
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€262.20
03.07.23
€270.00
03.07.24
-25.51%
27.04.24

Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Traumtanz 
03.07.23 50%
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€262.20
03.07.23
€270.00
03.07.24
-25.51%
27.04.24

Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Traumtanz 
03.07.23 50%
buy
Biogen Inc.

Start price
Target price
Perf. (%)
€262.20
03.07.23
€270.00
03.07.24
-25.51%
27.04.24

Good rating
Standard Investments for future growth
Innovative
Differentiated customer and product portfolio
Traumtanz 
03.07.23 50%
buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€1.31
16.04.24
-
16.04.25
4.98%
27.04.24

Global_Player 
16.04.24 50%
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.60
25.04.24
-
25.04.25
-1.53%
27.04.24

Could be worthwhile Investment >10% per year
Global_Player 
25.04.24 50%
buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€1.85
25.04.24
-
25.04.25
-4.27%
27.04.24

Global_Player 
25.04.24 50%
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€3.73
25.04.24
-
25.04.25
2.28%
27.04.24

Risky Investment
Global_Player 
25.04.24 50%
sell
Advaxis Inc.

Start price
Target price
Perf. (%)
€0.059
26.04.23
-
26.04.24
-
27.04.24

StockNews.com 
26.04.23 50%
buy
Arrowhead Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€30.42
26.04.23
€72.10
26.04.24
-32.05%
27.04.24

Sumitomo Mitsui Financial Group, Inc. 
26.04.23 50%
buy
Masimo Corp.

Start price
Target price
Perf. (%)
€172.00
26.04.23
-
26.04.24
-26.05%
27.04.24

Shooter 
26.04.23 50%
buy
Avenue Therapeutics Inc.

Start price
Target price
Perf. (%)
€0.81
26.04.23
-
26.04.24
-89.67%
27.04.24

kugelmann 
26.04.23 0%
buy
Riot Blockchain Inc.

Start price
Target price
Perf. (%)
€10.85
23.04.24
€15.00
23.04.25
2.75%
27.04.24

skatcup 
23.04.24 90%
sell
Abeona Therapeutics Inc.

Start price
Target price
Perf. (%)
€3.68
23.04.24
-
23.04.25
-16.85%
27.04.24

me8 
23.04.24 0%
sell
Adaptimmune Therapeutics PLC ADR

Start price
Target price
Perf. (%)
€1.07
13.04.24
€1.00
13.04.25
-6.54%
27.04.24

Probably not worthwhile Investment
Lower EBIT Margin than peer group
Bad rating
ROE lower than 10% per year
nvestor 
13.04.24 50%
sell
Inotiv Inc.

Start price
Target price
Perf. (%)
€5.50
13.04.24
€4.00
13.04.25
-31.27%
27.04.24

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Little Investments for future growth
nvestor 
13.04.24 50%
sell
Enlivex Therapeutics Ltd.

Start price
Target price
Perf. (%)
€1.51
13.04.24
€2.00
13.04.25
-9.27%
27.04.24

negative Cash Flow expected
Few uniques
Growths slower than the competition
Below average Marketposition
nvestor 
13.04.24 50%